1096 related articles for article (PubMed ID: 3018223)
21. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
Hess EJ; Battaglia G; Norman AB; Creese I
Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
[TBL] [Abstract][Full Text] [Related]
22. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
23. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
24. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
Beninger RJ; Mazurski EJ; Hoffman DC
Pol J Pharmacol Pharm; 1991; 43(6):507-28. PubMed ID: 1687945
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
26. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
Byrnes EM; Bruno JP
Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
[TBL] [Abstract][Full Text] [Related]
27. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
Onali P; Olianas MC; Gessa GL
Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
[TBL] [Abstract][Full Text] [Related]
28. Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists.
Cauli O; Morelli M
Psychopharmacology (Berl); 2002 Jul; 162(3):246-54. PubMed ID: 12122482
[TBL] [Abstract][Full Text] [Related]
29. Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment: assessment of the role of D1 dopamine receptor stimulation.
Rowlett JK; Mattingly BA; Bardo MT
Synapse; 1993 Jun; 14(2):160-8. PubMed ID: 8332946
[TBL] [Abstract][Full Text] [Related]
30. The role of dopaminergic systems in opioid receptor desensitization in nucleus accumbens and caudate putamen of rat after chronic morphine treatment.
Noble F; Cox BM
J Pharmacol Exp Ther; 1997 Nov; 283(2):557-65. PubMed ID: 9353370
[TBL] [Abstract][Full Text] [Related]
31. Repeated amphetamine administration alters the interaction between D1-stimulated adenylyl cyclase activity and calmodulin in rat striatum.
Roseboom PH; Hewlett GH; Gnegy ME
J Pharmacol Exp Ther; 1990 Oct; 255(1):197-203. PubMed ID: 2145422
[TBL] [Abstract][Full Text] [Related]
32. Expression of the bovine striatal D2 receptor, but not the D1 receptor, in bovine adrenal medulla.
Maroto R; López MG; del Valle M; Naranjo JR; Mellström B; García AG
Mol Pharmacol; 1995 Jan; 47(1):40-50. PubMed ID: 7838132
[TBL] [Abstract][Full Text] [Related]
33. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
Schmidt HD; Pierce RC
Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
[TBL] [Abstract][Full Text] [Related]
34. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
35. Electrophysiological verification of the presence of D1 and D2 dopamine receptors within the ventral pallidum.
Napier TC; Maslowski-Cobuzzi RJ
Synapse; 1994 Jul; 17(3):160-6. PubMed ID: 7974198
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
[TBL] [Abstract][Full Text] [Related]
37. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
38. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.
Cory-Slechta DA; Widzowski DV; Newland MC
J Pharmacol Exp Ther; 1989 Sep; 250(3):800-8. PubMed ID: 2789282
[TBL] [Abstract][Full Text] [Related]
39. Role of D1 and D2 dopamine receptors in mediating locomotor activity elicited from the nucleus accumbens of rats.
Dreher JK; Jackson DM
Brain Res; 1989 May; 487(2):267-77. PubMed ID: 2525062
[TBL] [Abstract][Full Text] [Related]
40. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
Breese GR; Napier TC; Mueller RA
J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
